Last updated: March 15, 2026
What Are the Current Market Trends for Corticosteroids?
The global corticosteroid market generated approximately $9 billion in revenue in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4% from 2023 to 2030. The key drivers include rising prevalence of inflammatory, autoimmune, and respiratory diseases, increased healthcare spending, and expanding indications for existing corticosteroid drugs.
Segment breakdown by application:
| Segment |
Market Share (2022) |
Key Drugs |
| Respiratory (e.g., asthma, COPD) |
45% |
Fluticasone, Budesonide |
| Dermatology |
25% |
Beclomethasone, Hydrocortisone |
| Autoimmune Disorders |
15% |
Prednisone, Methylprednisolone |
| Others (e.g., allergic conditions) |
15% |
Triamcinolone |
Regional analysis indicates North America holds 40% of the market, with Europe accounting for 30%, due to high prevalence rates and advanced healthcare infrastructure.
What Are the Main Competitive Players in This Market?
Major companies include:
- GlaxoSmithKline (GSK): Leading with inhaled corticosteroids like Fluticasone.
- AstraZeneca: Known for Budesonide products.
- Pfizer: Offers various corticosteroid formulations.
- Mylan (now part of Viatris): Focuses on generic corticosteroids.
- Teva Pharmaceutical Industries: Focuses on generics and biosimilars.
Market share concentration remains high, with the top five companies controlling over 70% of the market.
How Does the Patent Landscape Look?
The patent landscape for corticosteroids is complex, with a mix of expired patents allowing generics and active patent protections on novel formulations or delivery mechanisms.
Patent Lifespan and Expiration
| Drug |
Original Patent Expiry |
Patent Expiry Extension |
Notable Patent Details |
| Fluticasone Propionate |
2010 |
2018 (via supplementary protection certificates) |
Patented for inhalation delivery, with formulations patented separately |
| Budesonide |
2013 |
No extensions |
Patents on controlled-release formulations |
| Beclomethasone Dipropionate |
2005 |
Expired |
Generic versions available since 2006 |
Most original patents for inhaled corticosteroids expired between 2010 and 2015, enabling generic competition. However, patents covering specific formulations, device delivery methods, or new uses remain active, often providing market exclusivity beyond the expiration of basic drug patents.
Patents on Delivery Systems and Formulations
Innovation in inhaler devices and sustained-release formulations continues to be patent-protected. Patents in this category can extend exclusivity by 5-10 years, delaying generic entry despite expiration of drug substance patents.
What Are the Challenges and Opportunities?
Challenges:
- Patent expirations induce price competition and erode margins.
- Regulatory hurdles for new formulations or delivery systems.
- Patent litigation related to delivery technology and formulation specifics.
Opportunities:
- Development of biosimilar corticosteroids.
- Custom delivery systems improving bioavailability and patient compliance.
- Expanding indications for existing corticosteroids, including dermatologic and ophthalmic uses.
What’s Next in Patent Strategies?
Patent holders pursue:
- Method-of-use patents for new indications.
- Formulation patents that improve drug stability or absorption.
- Device patents for inhalers and topical delivery systems.
Patent protection strategies focus heavily on device-specific innovations, which can be protected separately from the drug compound itself.
Key Takeaways
The corticosteroid market is mature, with significant revenue derived from respiratory and dermatology applications. Patent expirations since 2010 created substantial generic competition, reducing prices and margins. However, patents on delivery mechanisms and new uses prolong market exclusivity for some brands. Companies focus on device innovations and formulation patents to maintain competitive advantages.
FAQs
-
When do most corticosteroid patents expire?
Primary patents expired between 2010 and 2015, but formulation and device patents remain in force.
-
What is the growth outlook for corticosteroid drugs?
The market is expected to grow at a CAGR of around 4% through 2030, driven by increased disease prevalence and new formulation development.
-
Are biosimilar corticosteroids part of the patent landscape?
Biosimilars are less relevant for small-molecule corticosteroids but are increasingly considered for injectable or innovative delivery systems.
-
How do patent strategies vary across companies?
Companies often patent delivery systems and new indications to extend market exclusivity beyond original compound patents.
-
What challenges do generic manufacturers face?
They encounter patent litigation on device patents and formulations, alongside regulatory approvals for bioequivalence.
References
[1] MarketLine. (2022). "Global Corticosteroids Market Analysis."
[2] IQVIA. (2023). "Pharmaceutical Market Reports."
[3] U.S. Patent and Trademark Office. (2023). Patent database search.
[4] European Patent Office. (2022). Patent Landscape Reports on Inhalation Devices.
